var data={"title":"Sumatriptan: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sumatriptan: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7004?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=sumatriptan-patient-drug-information\" class=\"drug drug_patient\">see &quot;Sumatriptan: Patient drug information&quot;</a> and <a href=\"topic.htm?path=sumatriptan-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Sumatriptan: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224276\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Alsuma [DSC];</li>\n      <li>Imitrex;</li>\n      <li>Imitrex STATdose Refill;</li>\n      <li>Imitrex STATdose System;</li>\n      <li>Onzetra Xsail;</li>\n      <li>Sumavel DosePro;</li>\n      <li>Zembrace SymTouch</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224277\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Imitrex DF;</li>\n      <li>Imitrex Injection;</li>\n      <li>Imitrex Nasal Spray;</li>\n      <li>Sumatriptan DF</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224322\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antimigraine Agent;</li>\n      <li>\n        Serotonin 5-HT<sub>1B, 1D</sub> Receptor Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224280\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Migraine:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i> A single dose of 25 mg, 50 mg, or 100 mg (taken with fluids). If a satisfactory response has not been obtained at 2 hours, a second dose may be administered. Results from clinical trials show that initial doses of 50 mg and 100 mg are more effective than doses of 25 mg, and that 100 mg doses do not provide a greater effect than 50 mg and may have increased incidence of side effects. Although doses of up to 300 mg/day have been studied, the total daily dose should not exceed 200 mg. The safety of treating an average of &gt;4 headaches in a 30-day period have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intranasal:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Powder: A single dose of 22 mg (11 mg nosepiece in each nostril). If headache has not resolved within 2 hours or returns, the dose may be repeated once &ge;2 hours after the first dose (maximum: 44 mg [4 nosepieces] per 24 hours or 22 mg [2 nosepieces] and one dose of another sumatriptan product [separated by &ge;2 hours] per 24 hours). The safety of treating an average of &gt;4 headaches in a 30-day period has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Solution: A single dose of 5 mg, 10 mg, or 20 mg administered in one nostril. A 10 mg dose may be achieved by administering a single 5 mg dose in each nostril. If headache has not resolved within 2 hours or returns, the dose may be repeated once after 2 hours, not to exceed a total daily dose of 40 mg. In clinical trials, a greater number of patients responded to initial doses of 20 mg versus 5 or 10 mg. The safety of treating an average of &gt;4 headaches in a 30-day period has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>SubQ:</i> Initial:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alsuma: 6 mg; Imitrex: 6 mg, if side effects are dose limiting, use lower doses 1 to 5 mg; Sumavel: 6 mg, if side effects are dose limiting, use 4 mg. May repeat if needed &ge;1 hour after initial dose (maximum: 6 mg per dose; two 6 mg injections per 24-hour period; or maximum cumulative dose of 12 mg in 24 hours, separated by at least 1 hour). However, controlled clinical trials have failed to document a benefit with administration of a second 6 mg dose in nonresponders.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Zembrace: 3 mg; may repeat if needed (up to 4 injections) with each injection separated by at least 1 hour (may also give following the dose of another sumatriptan product if separated by at least 1 hour); do not exceed 12 mg in 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cluster headache:</b> SubQ (excluding Zembrace): Initial: 6 mg; may repeat if needed &ge;1 hour after initial dose (maximum: 6 mg per dose; two 6 mg injections per 24-hour period). However, controlled clinical trials have failed to document a benefit with administration of a second 6 mg dose in nonresponders.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062222\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224281\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). However, dosage adjustment not expected due to extensive metabolism to inactive agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224282\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate hepatic impairment:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Bioavailability of oral sumatriptan is increased with liver disease. If treatment is needed, do not exceed single doses of 50 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied). However, because the solution and powder do not undergo first-pass metabolism, levels would not be expected to be altered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Subcutaneous: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe hepatic impairment: Oral, intranasal, and subcutaneous (Alsuma, Imitrex, and Zembrace injection) formulations are contraindicated in severe hepatic impairment. Sumavel is not recommended in severe hepatic impairment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224252\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Exhaler Powder, Nasal, as succinate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Onzetra Xsail: 11 mg per nosepiece (2 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Nasal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imitrex: 5 mg/actuation (1 ea); 20 mg/actuation (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/actuation (1 ea); 20 mg/actuation (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous, as succinate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imitrex: 6 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imitrex STATdose Refill: 4 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imitrex STATdose System: 4 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/0.5 mL (0.5 mL); 6 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous, as succinate [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 6 mg/0.5 mL (0.5 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Auto-injector, Subcutaneous, as succinate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Alsuma: 6 mg/0.5 mL (0.5 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imitrex STATdose System: 6 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zembrace SymTouch: 3 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/0.5 mL (0.5 mL); 6 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Cartridge, Subcutaneous, as succinate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imitrex STATdose Refill: 6 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Jet-injector, Subcutaneous, as succinate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Sumavel DosePro: 4 mg/0.5 mL (0.5 mL [DSC]); 6 mg/0.5 mL (0.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Subcutaneous, as succinate [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 6 mg/0.5 mL (0.5 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as succinate [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Imitrex: 25 mg, 50 mg, 100 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224238\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224256\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer as soon as symptoms appear.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Powder: For intranasal administration with the Xsail device only. Remove the clear device cap from the reusable delivery device; remove one 11 mg disposable nosepiece from the foil pouch and click into the device body. Prior to administration, pierce the capsule inside the nosepiece by pressing and releasing the white piercing button one time on the device body. Insert the nosepiece into one nostril so there is a tight seal; rotate the device to place the mouthpiece in the mouth. Blowing forcefully through the mouthpiece for 2 to 3 seconds will deliver the powder into the nasal cavity; vibration may occur. Do not press white button while blowing into mouthpiece. Once administered into the first nostril, remove and discard nosepiece; repeat same process using a second 11 mg nosepiece into the other nostril to administer the remainder of the 22 mg dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution: Each nasal spray unit is preloaded with 1 dose; <b>do not </b>test the spray unit before use; remove unit from plastic pack when ready to use; while sitting down, gently blow nose to clear nasal passages; keep head upright and close one nostril gently with index finger; hold container with other hand, with thumb supporting bottom and index and middle fingers on either side of nozzle; insert nozzle into nostril about <sup>1</sup>/<sub>2</sub> inch; close mouth; take a breath through nose while releasing spray into nostril by pressing firmly on blue plunger; remove nozzle from nostril; keep head level for 10 to 20 seconds and gently breathe in through nose and out through mouth; <b>do not breathe deeply</b>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Not for IM or IV use. Needle penetrates <sup>1</sup>/<sub>4</sub> inch of skin; use in areas of the body with adequate skin and subcutaneous thickness (lateral thigh or upper arm). In patients receiving doses other than 4 or 6 mg, use the 6 mg single-dose vial instead of the autoinjector device.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Needleless administration (Sumavel DosePro): Administer to the abdomen (&gt;2 inches from the navel) or thigh; not for IM or IV administration. Do not administer to other areas of the body (eg, arm). Device is for single use only, discard after use; do not use if the tip of the device is tilted or broken.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224255\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Migraine:</b> Intranasal, Oral, SubQ: Acute treatment of migraine with or without aura in adults</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cluster headache:</b> SubQ (excluding Zembrace): Acute treatment of cluster headache episodes in adults</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25856305\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Migraine (children/adolescents) (Intranasal); Migraine (children/adolescents) (Oral); Migraine (children/adolescents) (SubQ)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224330\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">SUMAtriptan may be confused with SAXagliptin, SITagliptin, somatropin, ZOLMitriptan</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224245\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Injection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Tingling sensation (14%), dizziness (&le;12%), vertigo (&le;12%), feeling hot (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction (59%), warm sensation at injection site (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Flushing (7%), chest discomfort (5%), chest tightness (3%), local discomfort (jaw or throat: 2% to 3%), chest pressure (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Burning sensation (7%), feeling of heaviness (7%), sensation of pressure (7%), numbness (5%), paresthesia (5%), sensation of tightness (5%), drowsiness (&le;3%), sedation (&le;3%), headache (2%), strange feeling (2%), tight feeling in the head (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea and vomiting (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Neck pain (&le;5%), neck stiffness (&le;5%), weakness (5%), myalgia (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasal discomfort (nasal cavity: &le;2%), sinus discomfort (&le;2%), bronchospasm (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Nasal:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysgeusia (&le;25%), unusual taste (&le;25%), nausea (&le;14%), vomiting (&le;14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasal discomfort (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Localized numbness (&le;5%), nasal cavity pain (&le;5%), paresthesia (&le;5%), dizziness (&le;2%), vertigo (&le;2%), localized burning (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Local irritation (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinorrhea (&le;5%), sore nose (&le;5%), nasal signs and symptoms (&le;4%), sinus discomfort (&le;4%), rhinitis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Tablet:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hot and cold flashes (3%), chest pain (&le;2%), chest pressure (&le;2%), chest tightness (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (&le;8%), sensation of pressure (&le;8%), paresthesia (3% to 5%), fatigue (&le;3%), feeling of heaviness (&le;3%), malaise (&le;3%), sensation of tightness (&le;3%), heaviness of chest (&le;2%), vertigo (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Sore throat (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Local pain (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Jaw pain (&le;3%), jaw pressure (&le;3%), jaw tightness (&le;3%), neck pain (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Pharyngeal edema (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Route unspecified:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Ischemia, Raynaud phenomenon</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Splenic infarction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, anaphylaxis, angioedema, blindness, cerebral hemorrhage, cerebrovascular accident, dystonia, heaviness in neck (includes jaw or throat), hypersensitivity reaction, hypotension, myocardial infarction, neck pressure, neck tightness, seizure, subarachnoid hemorrhage, tremor, vision loss (partial)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224259\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, angioedema, anaphylaxis) to sumatriptan or any component of the formulation; ischemic heart disease or signs or symptoms of ischemic heart disease (coronary artery vasospasm, Prinzmetal angina, angina pectoris, myocardial infarction, silent myocardial ischemia); history of cerebrovascular syndromes (including strokes, transient ischemic attacks), history of hemiplegic or basilar migraine; peripheral vascular disease (including ischemic bowel disease); uncontrolled hypertension; use within 24 hours of ergotamine derivatives; use within 24 hours of another 5-HT<sub>1</sub> agonist; concurrent administration or within 2 weeks of discontinuing an MAO type A inhibitors; Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders; severe hepatic impairment (excluding Sumavel)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224242\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactic/anaphylactoid reactions: Anaphylactic, anaphylactoid, and hypersensitivity reactions (including angioedema) have been reported; may be life threatening or fatal.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiac events: Coronary artery vasospasm, transient ischemia, myocardial infarction, ventricular tachycardia/fibrillation, cardiac arrest, and death have been reported with 5-HT<sub>1</sub> agonist administration (some occurring within a few hours of administration). Discontinue sumatriptan if these events occur. Patients who experience sensations of chest pain/pressure/tightness or symptoms suggestive of angina following dosing should be evaluated for coronary artery disease or Prinzmetal angina before receiving additional doses; if dosing is resumed and similar symptoms recur, monitor with ECG.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cerebrovascular events: Cerebral/subarachnoid hemorrhage and stroke (may be fatal) have been reported with 5-HT<sub>1</sub> agonist administration. Discontinue sumatriptan if a cerebrovascular event occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, such as dizziness, weakness, or drowsiness, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elevated blood pressure: Significant elevation in blood pressure, including hypertensive crisis, has been reported on rare occasions in patients with and without a history of hypertension. Use is contraindicated in patients with uncontrolled hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: Transient and permanent blindness and significant partial vision loss have been reported (rare) with use of 5-HT<sub>1</sub> agonist.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Serotonin syndrome may occur with 5-HT<sub>1</sub> agonists, particularly when used concomitantly with other serotonergic drugs; symptoms (eg, diarrhea, hyperreflexia, hyperthermia, incoordination, mental status changes, nausea, tachycardia, vomiting) typically occur minutes to hours after initiation/dose increase of a serotonergic drug. Discontinue use if serotonin syndrome is suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vasospasm-related events: Peripheral vascular ischemia, GI vascular ischemia and infarction, splenic infarction, and Raynaud syndrome have been reported with 5-HT<sub>1</sub> agonists.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Coronary artery disease: Perform a cardiovascular evaluation in 5-HT<sub>1</sub> agonists-naive patients who have risk factors for CAD (eg, hypertension, hypercholesterolemia, smoker, obesity, diabetes, strong family history of CAD, menopause, male &gt;40 years of age) prior to initiation of therapy. Patients with suspected CAD should have cardiovascular evaluation to rule out CAD before considering use; if cardiovascular evaluation is &ldquo;satisfactory,&rdquo; first dose should be given in the health care provider's office (consider ECG monitoring). Periodic evaluation of cardiovascular status should be done in these patients during intermittent long-term use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use oral formulations of sumatriptan with caution (and with dosage limitations) in patients with mild to moderate hepatic impairment where treatment is necessary and advisable. Presystemic clearance of orally administered sumatriptan is reduced in hepatic impairment, leading to increased plasma concentrations; dosage reduction of the oral product is recommended. Non-oral routes of administration (intranasal, subcutaneous) do not undergo similar hepatic first-pass metabolism and are not expected to result in significantly altered pharmacokinetics in patients with hepatic impairment. Use of the oral, intranasal, Alsuma, Imitrex, and Zembrace injectable is contraindicated in severe hepatic impairment; Sumavel is not recommended in severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorders: Use with caution in patients with history of seizure disorder or in patients with a lowered seizure threshold; seizures have been reported after sumatriptan administration in patients with or without a history of seizures.</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution; perform a cardiovascular evaluation prior to initiation of therapy in elderly patients with cardiovascular risk factors (eg, diabetes, hypertension, smoking, obesity, strong family history of coronary artery disease) and periodically during intermittent long-term use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Only indicated for the acute treatment of migraine or cluster headache (depending on product); not indicated for migraine or cluster headache prophylaxis, or for the treatment of hemiplegic or basilar migraine. Acute migraine agents (eg, 5-HT<sub>1</sub> agonists, opioids, ergotamine, or a combination of the agents) used for 10 or more days per month may lead to worsening of headaches (medication overuse headache); withdrawal treatment may be necessary in the setting of overuse. If a patient does not respond to the first dose, the diagnosis of migraine or cluster headache should be reconsidered; rule out underlying neurologic disease in patients with atypical headache and in patients with no prior history of migraine or cluster headache.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300101\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224247\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9968&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droxidopa: Serotonin 5-HT1D Receptor Agonists may enhance the hypertensive effect of Droxidopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: May enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives.<b> Exceptions: </b>Nicergoline.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May decrease the metabolism of Serotonin 5-HT1D Receptor Agonists. Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin 5-HT1D Receptor Agonists: May enhance the adverse/toxic effect of SUMAtriptan.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Serotonin Modulators may enhance the adverse/toxic effect of TraMADol. The risk of seizures may be increased. TraMADol may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224249\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224262\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">In a study using full-term, healthy human placentas, limited amounts of sumatriptan were found to cross the placenta (Schenker 1995).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnancy outcome information for sumatriptan is available from a pregnancy registry sponsored by GlaxoSmithKline. As of September 2012, data were available for 617 pregnancies (626 infants/fetuses) exposed to sumatriptan (including 7 pregnancies also exposed to naratriptan). Following sumatriptan exposure, the risk of major birth defects following first trimester exposure was 4.2% and no consistent pattern of birth defects was observed. The pregnancy registry was closed to enrollment in January 2012 (Ephross 2014).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">An analysis of data collected between 1995 and 2008 using the Swedish Medical Birth Register reported pregnancy outcomes following 5-HT1B/1D agonist exposure. An increased risk of major congenital malformations was not observed following sumatriptan exposure (2,229 exposed during the first trimester) (K&auml;ll&eacute;n 2011). An increased risk of major congenital malformations was also not observed using data collected from a Norwegian pregnancy registry study. This study included 415 women who used sumatriptan during the first trimester of pregnancy between 2004 and 2007 (Nezvalov&aacute;-Henriksen 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">If treatment for cluster headaches is needed during pregnancy, sumatriptan may be used (J&uuml;rgens 2009). Other agents are preferred for the initial treatment of migraine in pregnancy (Da Silva 2012; MacGregor 2014; Williams 2012); however, sumatriptan may be considered if first-line agents fail (MacGregor 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224263\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sumatriptan is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The authors of a study calculated the mean relative infant dose (RID) of sumatriptan to be 3.5% when compared to a weight-adjusted maternal dose of 6 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The RID of sumatriptan was calculated using a mean milk concentration of 87.2 mcg/L (range: 61.9 to 112.5 mcg/L). This milk concentration was obtained following maternal administration of sumatriptan 6 mg SubQ as a single dose to 5 women (mean duration of lactation 22.2 weeks), and milk concentrations were measured over 8 hours. The median half-life in breast milk was 2.2 hours and the maximum milk concentrations occurred between 1.7 and 3.5 hours after the maternal dose (Wojnar-Horton 1996).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Following oral, subcutaneous, or intranasal administration, the manufacturers recommend withholding breastfeeding for 12 hours after the maternal dose. However, according to other sources, if treatment is needed, breastfeeding does not need to be discontinued (J&uuml;rgens 2009; MacGregor 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22815302\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Headache severity, blood pressure, signs/symptoms suggestive of angina; perform a cardiovascular evaluation prior to initiation of therapy in 5-HT<sub>1</sub> agonist-naive patients who have multiple cardiovascular risk factors (eg, increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD); monitor ECG with first dose in patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation and consider periodic cardiovascular evaluation in such patients during intermittent long-term use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224241\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Selective agonist for serotonin (5-HT<sub>1B</sub> and 5-HT<sub>1D</sub> receptors) on intracranial blood vessels and sensory nerves of the trigeminal system; causes vasoconstriction and reduces neurogenic inflammation associated with antidromic neuronal transmission correlating with relief of migraine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224258\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Oral: ~30 minutes; Intranasal: Solution: ~15 to 30 minutes; SubQ: ~10 minutes; Peak effect: Oral: 2 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub> (central): SubQ: 50 L; V<sub>d</sub> (apparent): Oral, Intranasal powder and solution: 2.7 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 14% to 21%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic to an indole acetic acid metabolite (inactive) which then undergoes ester glucuronide conjugation; may be metabolized by monoamine oxidase (MAO); extensive first-pass metabolism following oral administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Intranasal: Solution 17%, Powder 19% (compared to SubQ); Oral: 15%; SubQ: 97% &plusmn; 16%; <b> Note</b>: Sumavel DosePro is bioequivalent to sumatriptan SubQ injection via needle when administered into the thigh or abdomen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Distribution: 15 minutes; Terminal: 2 hours; range: 1 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: 2 to 2.5 hours; Intranasal: Powder: ~45 minutes; SubQ: 12 minutes (range: 4 to 20 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: Urine (42% of total dose as indole acetic acid metabolite; 3% of total dose as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Urine (~60% of total dose, mostly as indole acetic acid metabolite; 3% of total dose as unchanged drug); feces (~40%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: Urine (38% of total dose as indole acetic acid metabolite; 22% of total dose as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224261\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Exhaler Powder</b> (Onzetra Xsail Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">11MG/NOSEPC (2): $103.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Imitrex Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/ACT (1): $94.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/ACT (1): $94.98</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Imitrex Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/0.5 mL (0.5 mL): $221.87</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (SUMAtriptan Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/ACT (1): $61.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/ACT (1): $61.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (SUMAtriptan Succinate Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/0.5 mL (0.5 mL): $28.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Imitrex STATdose System Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/0.5 mL (0.5 mL): $237.84</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/0.5 mL (0.5 mL): $237.84</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (SUMAtriptan Succinate Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/0.5 mL (0.5 mL): $107.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/0.5 mL (0.5 mL): $187.03</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Zembrace SymTouch Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3 mg/0.5 mL (0.5 mL): $188.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Cartridge</b> (Imitrex STATdose Refill Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/0.5 mL (0.5 mL): $225.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6 mg/0.5 mL (0.5 mL): $225.26</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Imitrex Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (9): $314.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (9): $684.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (9): $684.86</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (SUMAtriptan Succinate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (9): $243.47</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (9): $226.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (9): $226.26</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F224264\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adracon (PE);</li>\n      <li>Apigrane (JO);</li>\n      <li>Cetatrex (ID);</li>\n      <li>Cinie (LV);</li>\n      <li>Fermig (MX);</li>\n      <li>Imigran (AE, AT, AU, BB, BG, BH, BM, BR, BS, BZ, CH, CL, CY, CZ, DE, DK, EC, EE, EG, ES, FI, GB, GR, GY, HK, HN, HR, HU, IE, IS, IT, JM, JO, KR, KW, LB, LK, LT, MT, MX, MY, NL, NO, NZ, PE, PH, PK, PL, PT, QA, RO, RU, SA, SE, SI, SK, SR, TH, TR, TT, TW, UY, VE, VN, ZW);</li>\n      <li>Imigran FDT (SG);</li>\n      <li>Imigran Nasal Spray (QA, SA);</li>\n      <li>Imigran Radis (GB);</li>\n      <li>Imigrane (FR);</li>\n      <li>Imihran (UA);</li>\n      <li>Imiject (FR);</li>\n      <li>Imitrex (BE, IL, LU);</li>\n      <li>Micranil (AR);</li>\n      <li>Migane (ET);</li>\n      <li>Migraban (QA);</li>\n      <li>Migragesin (CO);</li>\n      <li>Migraval (VE);</li>\n      <li>Na Chuan (CN);</li>\n      <li>Nograine (MX);</li>\n      <li>Nomigra (BD);</li>\n      <li>Rontadol (AR);</li>\n      <li>Sitran (CO);</li>\n      <li>Somatran (CL);</li>\n      <li>Sumagran (AU);</li>\n      <li>Sumalux (BD);</li>\n      <li>Sumamihren (UA);</li>\n      <li>Sumatab (AU);</li>\n      <li>Sumatan (BD);</li>\n      <li>Sumatran (IE, SG);</li>\n      <li>Sumatridex (IL);</li>\n      <li>Sumavel DosePro (DE, DK);</li>\n      <li>Sumax (BR);</li>\n      <li>Sumig (PH);</li>\n      <li>Sumitran (MY, SG);</li>\n      <li>Sumitrex (IN, MX);</li>\n      <li>Sutagran (VN);</li>\n      <li>Tebegran (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Akpunonu BE, Mutgi AB, and Federman DJ, &ldquo;Subcutaneous Sumatriptan for Treatment of Acute Migraine in Patients Admitted to the Emergency Department: A Multicenter Study,&rdquo; <i>Ann Emerg Med</i>, 1995, 25(4):464-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/7710149/pubmed\" target=\"_blank\" id=\"7710149\">7710149</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alsuma (sumatriptan) [prescribing information]. New York, NY: Pfizer; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi: 10.1002/cpt.377.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blier P and Bergeron R, &ldquo;The Safety of Concomitant Use of Sumatriptan and Antidepressant Treatments,&rdquo; <i>J Clin Psychopharmacol</i>, 1995, 15(2):106-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/7782482/pubmed\" target=\"_blank\" id=\"7782482\">7782482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boyd IW and Rohan AP, &ldquo;Sumatriptan - Induced Chest Pain,&rdquo; <i>Lancet</i>, 1994, 344(8939):1704-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/7996981/pubmed\" target=\"_blank\" id=\"7996981\">7996981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boyer EW and Shannon M, &ldquo;The Serotonin Syndrome,&rdquo; <i>New Engl J Med</i>, 2005, 352:1112-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/15784664/pubmed\" target=\"_blank\" id=\"15784664\">15784664</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cunnington M, Ephross S, and Churchill P, &quot;The Safety of Sumatriptan and Naratriptan in Pregnancy: What Have We Learned?&quot; <i>Headache</i>, 2009, 49(10):1414-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/19804390/pubmed\" target=\"_blank\" id=\"19804390\">19804390</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Curtin T, Brooks AP, and Roberts JA, &ldquo;Cardiorespiratory Distress After Sumatriptan Given by Injection,&rdquo; <i>BMJ</i>, 1992, 305(6855):713-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/1327368/pubmed\" target=\"_blank\" id=\"1327368\">1327368</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Da Silva AN and Tepper SJ, &quot;Acute Treatment of Migraines,&quot; <i>CNS Drugs</i>, 2012, 26(10):823-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/22823482/pubmed\" target=\"_blank\" id=\"22823482\">22823482</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diamond S, &ldquo;The Use of Sumatriptan in Patients on Monoamine Oxidase Inhibitors,&rdquo; <i>Neurology</i>, 1995, 45(6):1039-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/7783861/pubmed\" target=\"_blank\" id=\"7783861\">7783861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edwards KR, Bennington VT, and Ellis J, &ldquo;Intracerebral Hemorrhage Associated With Sumatriptan,&rdquo; <i>Headache</i>, 1995, 35:309.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ephross SA, Sinclair SM. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry. <i>Headache</i>. 2014;54(7):1158-1172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/24805878/pubmed\" target=\"_blank\" id=\"24805878\">24805878</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Safety Alert: MedWatch. FDA evaluating the risk of burns and scars with Zecuity (sumatriptan) migraine patch. Available at: <a href=\"http://www.fda.gov/Drugs/DrugSafety/ucm504588.htm\" target=\"_blank\">http://www.fda.gov/Drugs/DrugSafety/ucm504588.htm</a>. Accessed June 14, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imitrex injection (sumatriptan) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Imitrex tablets (sumatriptan) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi: 10.1056/NEJM200007133430208.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    J&uuml;rgens TP, Schaefer C, and May A, &quot;Treatment of Cluster Headache in Pregnancy and Lactation,&quot; <i>Cephalalgia</i>, 2009, 29(4):391-400.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/19170693/pubmed\" target=\"_blank\" id=\"19170693\">19170693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    K&auml;ll&eacute;n B, Nilsson E, and Otterblad Olausson P, &quot;Delivery Outcome After Maternal Use of Drugs for Migraine: A Register Study in Sweden,&quot; <i>Drug Saf</i>, 2011, 34(8):691-703.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/21751829/pubmed\" target=\"_blank\" id=\"21751829\">21751829</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly KM, &ldquo;Cardiac Arrest Following Use of Sumatriptan,&rdquo; <i>Neurology</i>, 1995, 45(6):1211-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/7783891/pubmed\" target=\"_blank\" id=\"7783891\">7783891</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    La Porta LD, &ldquo;Recurrent Depression After Sumatriptan Administration for Treatment of Migraine,&rdquo; <i>J Clin Psychopharmacol</i>, 1995, 15(1):81-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/7714232/pubmed\" target=\"_blank\" id=\"7714232\">7714232</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Luman W and Gray RS, &ldquo;Adverse Reactions Associated With Sumatriptan,&rdquo; <i>Lancet</i>, 1993, 341(8852):1091-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/8096980/pubmed\" target=\"_blank\" id=\"8096980\">8096980</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacDonald JT, &ldquo;Treatment of Juvenile Migraine With Subcutaneous Sumatriptan,&rdquo; <i>Headache</i>, 1994, 34(10):581-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/7843952/pubmed\" target=\"_blank\" id=\"7843952\">7843952</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacGregor EA. Migraine in pregnancy and lactation. <i>Neurol Sci</i>. 2014;35(Suppl 1):61-64. doi: 10.1007/s10072-014-1744-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/24867839/pubmed\" target=\"_blank\" id=\"24867839\">24867839</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23884894\"></a>Nezvalov&aacute;-Henriksen K, Spigset O, Nordeng H, et al. Triptan safety during pregnancy: a Norwegian population registry study. <i>Eur J Epidemiol</i>. 2013;28(9):759-769. doi: 10.1007/s10654-013-9831-x.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/23884894/pubmed\" target=\"_blank\" id=\"23884894\">23884894</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Onzetra Xsail (sumatriptan nasal powder) [prescribing information]. Aliso Viejo, CA: Avanir Pharmaceuticals; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orr SL, Friedman BW, Christie S, et al. Management of adults with acute migraine in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies. <i>Headache</i>. 2016;56(6):911-940.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/27300483/pubmed\" target=\"_blank\" id=\"27300483\">27300483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ottervanger JP, et al, &ldquo;Characteristics of Sumatriptan-Induced Chest Pain,&rdquo; <i>Pharm World Sci</i>, 1995, 17:3.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ottervanger JP, et al, &ldquo;Determinants of Sumatriptan-Induced Chest Pain,&rdquo; <i>Pharm World Sci</i>, 1995, 17:7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ottervanger JP, van Witsen TB, Valkenburg HA, et al, &ldquo;Adverse Reactions Attributed to Sumatriptan: A Postmarketing Study in General Practice,&rdquo; <i>Eur J Clin Pharmacol</i>, 1994, 47(4):305-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/7875179/pubmed\" target=\"_blank\" id=\"7875179\">7875179</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palmer J, Feldman R, Mancini GB, et al, &ldquo;Glyceryl Trinitrate Reversal of Post-Sumatriptan Coronary Artery Narrowing,&rdquo; <i>Lancet</i>, 1995, 345(8961):1366.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/7752771/pubmed\" target=\"_blank\" id=\"7752771\">7752771</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schenker S, Yang Y, Perez A, et al, &quot;Sumatriptan (Imitrex) Transport by the Human Placenta,&quot; <i>Proc Soc Exp Biol Med</i>, 1995, 210(3):213-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/8539258/pubmed\" target=\"_blank\" id=\"8539258\">8539258</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scott AK, &ldquo;Sumatriptan Clinical Pharmacokinetics,&rdquo; <i>Clin Pharmacokinet</i>, 1994, 27(5):337-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/7851052/pubmed\" target=\"_blank\" id=\"7851052\">7851052</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Srinivas NR, Igwenezue KB, Hainsworth JD, et al, &ldquo;Lack of Pharmacokinetic Interaction Between Butorphanol Tartrate Nasal Spray and Sumatriptan Succinate,&rdquo; <i>J Clin Pharmacol</i>, 1995, 35(4):432-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/7650235/pubmed\" target=\"_blank\" id=\"7650235\">7650235</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Srinivas NR, Shyu WC, Upmalis D, et al, &ldquo;Lack of Pharmacokinetic Interaction Between Butorphanol Tartrate Nasal Spray and Sumatriptan Succinate,&rdquo; <i>J Clin Pharmacol</i>, 1995, 35(4):432-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/7650235/pubmed\" target=\"_blank\" id=\"7650235\">7650235</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stricker BH, &ldquo;Coronary Vasospasm and Sumatriptan,&rdquo; <i>BMJ</i>, 1992, 305(6845):118.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/1322217/pubmed\" target=\"_blank\" id=\"1322217\">1322217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sumavel DosePro (sumatriptan) [prescribing information]. San Diego, CA: Zoginex Inc; October 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walton-Shirley M, Flowers K, and Whiteside JH, &ldquo;Unstable Angina Pectoris Associated With Imitrex Therapy,&rdquo; <i>Cathet Cardiovasc Diagn</i>, 1995, 34(2):188.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/7788702/pubmed\" target=\"_blank\" id=\"7788702\">7788702</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weidmann B, Jansen W, Bojko P, et al, &ldquo;Sumatriptan-Induced Myocardial Infarction,&rdquo; <i>Intensivmedizin und Nofallmediczin</i>, 1994, 31:353.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Williams SH and Kehr HA, &quot;An Update in the Treatment of Neurologic Disorders During Pregnancy-Focus on Migraines and Seizures,&quot; <i>J Pharm Pract</i>, 2012, 25(3):341-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/22550159/pubmed\" target=\"_blank\" id=\"22550159\">22550159</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wojnar-Horton RE, Hackett LP, Yapp P, et al, &quot;Distribution and Excretion of Sumatriptan in Human Milk,&quot; <i>Br J Clin Pharmacol</i>, 1996, 41(3):217-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sumatriptan-drug-information/abstract-text/8866921/pubmed\" target=\"_blank\" id=\"8866921\">8866921</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zembrace SymTouch (sumatriptan succinate) [prescribing information]. San Diego, CA: Dr. Reddy&rsquo;s; March 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9968 Version 217.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F224276\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F224277\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F224322\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F224280\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062222\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F224281\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F224282\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F224252\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F224238\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F224256\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F224255\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25856305\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F224330\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F224245\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F224259\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F224242\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300101\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F224247\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F224249\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F224262\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F224263\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F22815302\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F224241\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F224258\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F224261\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F224264\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9968|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=sumatriptan-patient-drug-information\" class=\"drug drug_patient\">Sumatriptan: Patient drug information</a></li><li><a href=\"topic.htm?path=sumatriptan-pediatric-drug-information\" class=\"drug drug_pediatric\">Sumatriptan: Pediatric drug information</a></li></ul></div></div>","javascript":null}